Abstract
Natural compounds are proper tools for inhibiting cancer cell proliferation. Hence, the search for these ligands of overexpressed receptors in breast cancer has been a competitive challenge recently and opens new avenues for drug discovery. In this research, we have investigated molecular interactions between natural products and overexpressed receptors in breast cancer using molecular docking and dynamic simulation approaches followed by extraction of the best ligand from Citrus limetta and developing for nanoscale encapsulation composed of soy lecithin using a sonicator machine. The encapsulation process was confirmed by DLS and TEM analyses. Anticancer activity was also examined using MTT method. Among the investigated natural compounds, hesperidin was found to bind to specific targets with stronger binding energy. The molecular dynamics results indicated that the hesperidin-MCL-1 complex is very stable at 310.15 K for 200 ns. The RP-HPLC analysis revealed that the purity of extracted hesperidin was 98.8% with a yield of 1.72%. The results of DLS and TEM showed a strong interaction between hesperidin and lecithin with an entrapped efficiency of 92.02 ± 1.08%. Finally, the cytotoxicity effect of hesperidin was increased against the MDA-MB-231 cell line with an IC50 value of 62.93 μg/mL after encapsulation, whereas no significant effect against the MCF10A cell line. We showed for the first time that hesperidin is a flexible and strong ligand for the MCL-1 receptor. Also, it has the in vitro ability to kill the MDA-MB-231 cell lines without having a significant effect on the MCF10A cell lines. Therefore, hesperidin could be used as a food ingredient to generate functional foods.
Publisher
Public Library of Science (PLoS)
Reference43 articles.
1. New Insights into the Screening, Prompt Diagnosis, Management, and Prognosis of Breast Cancer.;P-RJ Domeyer;Journal of Oncology,2020
2. Bridging molecular docking to molecular dynamics in exploring ligand-protein recognition process: An overview.;V Salmaso;Frontiers in pharmacology,2018
3. Targeted therapies in breast cancer: New challenges to fight against resistance.;V Masoud;World journal of clinical oncology,2017
4. Identification by molecular docking of homoisoflavones from Leopoldia comosa as ligands of estrogen receptors.;F Grande;Molecules,2018
5. Differential expression of estrogen receptor α, β1, and β2 in lobular and ductal breast cancer;B Huang;Proceedings of the National Academy of Sciences,2014
Cited by
42 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献